Lisata Therapeutics, Inc. (LSTA) NASDAQ
3.08
-0.2(-6.10%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
3.08
-0.2(-6.10%)
Currency In USD
Address
110 Allen Road
Basking Ridge, NJ 07920
United States of America (the)
Phone
908 842 0100
Website
Sector
Healthcare
Industry
Biotechnology
Employees
26
First IPO Date
March 01, 1999
| Name | Title | Pay | Year Born |
| David J. Mazzo | President, Chief Executive Officer & Director | 735,479 | 1957 |
| William K. Sietsema | Vice President of Global Regulatory Affairs | 350,554 | 1957 |
| James Nisco | Senior Vice President of Finance, Treasurer, CAO & Principal Financial and Accounting Officer | 358,250 | 1972 |
| Kristen K. Buck | Executive Vice President of R&D and Chief Medical Officer | 607,592 | 1975 |
| Gregory S. Berkin | Chief Information & Data Protection Officer | 0 | N/A |
| John D. Menditto | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Tariq Imam | Senior Vice President of Business Development & Operations and General Counsel | 0 | 1984 |
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.